MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2189-2198

  Li, X J ^a   Luo, X Q ^a   Han, B W ^a   Duan, F T ^a   Wei, P P ^a   Chen, Y Q ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

acute lymphoblastic leukaemia; apoptosis; FKBP51 signalling; IGF1R mTOR signalling pathway; miRNA; proliferation

Indexed keywords

DEXAMETHASONE; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 51; GLUCOCORTICOID RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 100; MICRORNA 99A; PROTEIN MCL 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHILD; DOWN-REGULATION; HEK293 CELLS; HUMANS; JURKAT CELLS; MICRORNAS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TACROLIMUS BINDING PROTEINS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84885909874     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.562     Document Type: Article

References (52)

1. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L, San Jose-Eneriz E, Abizanda G, Rodriguez-Otero P, Fortes P, Rifon J, Bandres E, Calasanz MJ, Martin V, Heiniger A, Torres A, Siebert R, Roman-Gomez J, Prosper F (2009) Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69(10): 4443-4453.
2. Bai J, Guo A, Hong Z, Kuai W (2012) Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. OncoTargets Ther 5: 213-219.
3. Baughman G, Wiederrecht GJ, Campbell NF, Martin MM, Bourgeois S (1995) FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol 15(8): 4395-4402.
4. Bhushan L, Kandpal RP (2011) EphB6 receptor modulates micro RNA profile of breast carcinoma cells. PloS One 6(7): e22484.
5. Binder EB (2009) The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34(Suppl 1): S186-S195.
6. Bray PJ, Cotton RG (2003) Variations of the human glucocorticoid receptor gene (NR3C1): Pathological and in vitro mutations and polymorphisms. Human Mutat 21(6): 557-568.
7. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30(23): 2919-2928.
8. Cardoso BA, Martins LR, Santos CI, Nadler LM, Boussiotis VA, Cardoso AA, Barata JT (2009) Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia 23(1): 206-208.
9. Chen DW, Saha V, Liu JZ, Schwartz JM, Krstic-Demonacos M (2012a) Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia. Oncogene 32(25): 3039-3048.
10. Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, Hittelman AB, Rogatsky I, Logan SK, Garabedian MJ (2008) Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 22(8): 1754-1766.
11. Chen Z, Jin Y, Yu D, Wang A, Mahjabeen I, Wang C, Liu X, Zhou X (2012b) Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol 48(8): 686-691.
12. Davies TH, Ning YM, Sanchez ER (2002) A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem 277(7): 4597-4600.
13. Denny WB, Prapapanich V, Smith DF, Scammell JG (2005) Structurefunction analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology 146(7): 3194-3201.
14. Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG (2000) Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 141(11): 4107-4113.
15. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP, Lalli E (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 70(11): 4666-4675.
16. Echeverria PC, Mazaira G, Erlejman A, Gomez-Sanchez C, Piwien Pilipuk G, Galigniana MD (2009) Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. Mol Cell Biol 29(17): 4788-4797.
17. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A (2012) Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 38(6): 698-707.
18. Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nature Rev Cancer 6(4): 259-269.
19. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR (2005) Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 173(5): 1772-1777.
20. Fernando TR, Rodriguez-Malave NI, Rao DS (2012) MicroRNAs in B cell development and malignancy. J Hematol Oncol 5: 7.
21. Hertel J, Bartschat S, Wintsche A, Otto C, Stadler PF (2012) Evolution of the let-7 microRNA family. RNA Biol 9(3): 231-241.
22. Hirsch E, Chiarle R (2012) Calming down T cell acute leukemia. Cancer Cell 21(4): 449-450.
23. Hwang HW, Mendell JT (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94(6): 776-780.
24. Jiang W, Cazacu S, Xiang C, Zenklusen JC, Fine HA, Berens M, Armstrong B, Brodie C, Mikkelsen T (2008) FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia 10(3): 235-243.
25. Johnston PB, Yuan R, Cavalli F, Witzig TE (2010) Targeted therapy in lymphoma. J Hematol Oncol 3: 45.
26. Kraszewska MD, Dawidowska M, Szczepanski T, Witt M (2012) T-cell acute lymphoblastic leukaemia: Recent molecular biology findings. Br J Haematol 156(3): 303-315.
27. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2): 274-293.
28. Lerman G, Avivi C, Mardoukh C, Barzilai A, Tessone A, Gradus B, Pavlotsky F, Barshack I, Polak-Charcon S, Orenstein A, Hornstein E, Sidi Y, Avni D (2011) MiRNA expression in psoriatic skin: Reciprocal regulation of hsamiR- 99a and IGF-1R. PloS One 6(6): e20916.
29. Li L, Lou Z, Wang L (2011) The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer 104(1): 19-23.
30. Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, Trumpp A, Pflumio F, Carboni J, Gottardis M, Pollak M, Kung AL, Aster JC, Holzenberger M, Weng AP (2011) High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med 208(9): 1809-1822.
31. Mills JR,Hippo Y, Robert F, Chen SM,MalinaA, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, Kogan SC, Nadon R, Housman DE, Lowe SW, Pelletier J (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105(31): 10853-10858.
32. Molitoris JK, McColl KS, Distelhorst CW (2011) Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17B92 contributes to the induction of Bim and initiation of apoptosis. Mol Endocrinol 25(3): 409-420.
33. Mueller AC, Sun D, Dutta A (2012) The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 32(9): 1164-1172.
34. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L (2009) FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16(3): 259-266.
35. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N (2006) mTOR signaling: Implications for cancer and anticancer therapy. Br J Cancer 94(2): 195-199.
36. Pui CH, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. N Engl J Med 350(15): 1535-1548.
37. Ratajczak T, Ward BK, Minchin RF (2003) Immunophilin chaperones in steroid receptor signalling. Curr Top Med Chem 3(12): 1348-1357.
38. Rees-Unwin KS, Craven RA, Davenport E, Hanrahan S, Totty NF, Dring AM, Banks RE, J Morgan G, Davies FE (2007) Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma. Br J Haematol 139(4): 559-567.
39. Rogatsky I, Ivashkiv LB (2006) Glucocorticoid modulation of cytokine signaling. Tissue Antigens 68(1): 1-12.
40. Romano S, Sorrentino A, Di Pace AL, Nappo G, Mercogliano C, Romano MF (2011) The emerging role of large immunophilin FK506 binding protein 51 in cancer. Curr Med Chem 18(35): 5424-5429.
41. Schmidt MV, Paez-Pereda M, Holsboer F, Hausch F (2012) The prospect of FKBP51 as a drug target. Chem Med Chem 7(8): 1351-1359.
42. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S (2012) MiR-125 in normal and malignant hematopoiesis. Leukemia 26(9): 2011-2018.
43. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, Jensen RV, Moskaluk CA, Dutta A (2011) miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 71(4): 1313-1324.
44. Tognon CE, Sorensen PH (2012) Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 16(1): 33-48.
45. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R (2012) Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 12: 369.
46. Vandevyver S, Dejager L, Libert C (2012) On the trail of the glucocorticoid receptor: Into the nucleus and back. Traffic 13(3): 364-374.
47. Wang Z, Frederick J, Garabedian MJ (2002) Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo. J Biol Chem 277(29): 26573-26580.
48. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10(4): 331-342.
49. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306(5694): 269-271.
50. Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F, Rein T (2005) FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem 280(6): 4609-4616.
51. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ (2009) MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PloS One 4(11): e7826.
52. Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, Lin KY, Zhou H, Qu LH, Zhang P, Chen YQ (2012) MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 31(1): 80-92.